By Ahmed Aboulenein WASHINGTON, Feb 1 (Reuters) - The U.S. Food and Drug Administration on Sunday began accepting requests to ...

Key market opportunities in the CDMO sector include rising outsourcing demands for biologics and HPAPIs, driven by R&D costs ...

Despite being saddled with tariffs and lagging behind China and the US, European sites offer biopharma suppliers a chance to ...

The FDA launched PreCheck pilot program to strengthen U.S. drug supply chain by improving regulatory predictability.

XINTAI, SHANDONG, CHINA, January 19, 2026 /EINPresswire.com/ -- In recent years, the global pharmaceutical packaging ...

“The global API manufacturing market is going through some major changes these days,” says Sean O’Brien, COO, Abzena. He ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro's drug product development and ...

FDA Commissioner Marty Makary, M.D., M.P.H., characterized the program as a “bold step” to bring manufacturing back to the US and make the domestic sector more resilient and competitive. This program ...

For much of the past decade, drug shortages in the United States were treated as episodic disruptions. In 2024, that framing ...

The pharmaceutical industry operates under an uncompromising mandate: zero defects. Every tablet, capsule, vial, or syringe must meet exacting standards for dosage, purity, and sterility. This ...

As supply chain vulnerabilities intensify and competition accelerates, the cost of this underutilization could risk India's ...